MANAGEMENT OF KLEBSIELLA PNEUMONIAE KPC OUTBREAK IN INTERNAL MEDICINE
|
|
- Gerald Kelley
- 6 years ago
- Views:
Transcription
1 Acta Medica Mediterranea, 2016, 32: 823 MANAGEMENT OF KLEBSIELLA PNEUMONIAE KPC OUTBREAK IN INTERNAL MEDICINE ANDREA BELLODI 1*, LISETTE DEL CORSO 1, SERENA FAVORINI 1, ELISA MOLINARI 1, ERIKA COPPO 2, GIOVANNI ORENGO 3, VALERIO DEL BONO 4, RICCARDO GHIO 1, ELEONORA ARBOSCELLO 1 1 Clinic of Internal Medicine 3 IRCCS AOU San Martino IST, Genoa, Italy - 2 Microbiology IRCCS AOU San Martino IST, Genoa, Italy - 3 Clinic Risk and Quality Management, IRCCS AOU San Martino IST, Genoa, Italy - 4 Clinic of Infectious Diseases IRCCS AOU San Martino IST, Genoa, Italy ABSTRACT Introduction: Italy has a high incidence of Klebsiella pneumoniae producing carbapenemase (CRKP) infections. We report and discuss the experience of our Centre, an Internal Medicine Unit in North-Western Italy, focusing on the high clinical challenge dealing with this infections in year 2012 with data expanded over three years of surveillance Materials and methods: we retrospectively analyzed data of patients with isolation of CRKP during years Results: In patients had positive cultures for CRKP; in 2012 CRKP was isolated in 21 patients. The mean age of the cohort was 77,6 (range 52-89). Cultures were positive in different specimens: urines 71,4%, blood 9.52%, upper respiratory tract 9.52%, wounds 9,52%. Most relevant infection-associated risk factors were identified in presence of devices such as urinary catheter (UC) (76% of patients) or central venous catheter (CVC) (47% of patients). In 2013 we observed 6 cases. Cultures were positive on urines, blood and abdominal drainage, blood, sputum and bronchial-alveolar lavage. In conclusion, in three years of surveillance we observed 29 patients with CRKP isolation: 17 urinary tract infections (response 6/13), 4 blood stream infections (response 1/3), 4 respiratory tract infections (response 1/3), 4 skin and soft tissue infections/colonization (not treated); crude mortality was 51% and global response to therapy was 42,1% on 19 treated patients. Conclusions: the 2012 outbreak was contained and the major awareness of the problem produced systematic new measures for infection control: screening with rectal swab for CRKP for patients admitted from other Hospitals or wards, sudden isolation of colonized/infected patients, more accurate attention to environmental and personal hygiene. CRPK is an important cause of morbidity and mortality; efficiency of single agent antibiotic therapy against CRPK seems to be not satisfying. Dedicated guidelines of new combination therapy are required. Key words: Klebsiella pneumoniae KPC, carbapenemase, antibiotic resistance, outbreak, internal medicine, infection control. DOI: / _2016_3_97 Received Febrary 13, 2016; Accepted April 02, 2016 Introduction Klebsiella pneumoniae producing carbapenemase (CRKP) is one of the most fearful enemy for healthcare providers. First cases were described in the United States in 2001 from a strain isolated in 1996 (1). Carbapenemase (KPC) is a type of beta lactamase resistant to all beta lactam antibiotics, including carbapenems. KPC enzymes are located on plasmids (2) ; currently 10 variants of KPC have been discovered. Other gram-negative species (such as Escherichia coli, Proteus mirabilis, Enterobacter species, Salmonella enterica, Citrobacter freundii, Serratia species, Pseudomonas species and Acinetobacter baumannii) can carry these type of enzymes (3). Giani et al described the first case in Italy in 2008, with the isolation of KPC 3 with corresponding gene located on transposon tn4401, the same reported from some Israeli isolation (4). The current epidemiological data in Europe shows a sit-
2 824 Andrea Bellodi, Lisette Del Corso et Al uation even worse than expected in the early 2000: the numbers of the infections are near to pandemics, especially in Italy, Greece and Israel. Fortunately not all individuals who have contact with CRKP develop infection, sometimes just the colonization occurs (5). Inappropriate antibiotics therapies, travels and poor hygienic measures seem to be determinant elements that brought to such a spread of worldwide cases. Here we report and discuss the experience of our center, an Internal Medicine Unit in Italy, focusing on the high clinical challenge dealing with this infections across year 2012 and Materials and methods Setting San Martino Hospital is the largest acute tertiary care hospital in Liguria, Italy, with a total capability of about 1400 beds. Patients involved in the study derived from a single ward, the Clinic of Internal Medicine 3. This ward has a capability of 27 beds, with an annual number of admitted patients of about 750. Data are collected from January 2011 to December 2013 and they are analyzed retrospectively. Patients came from Emergency Care Unit or other units, especially Hematology and Surgery. Infection control policy did not include routine surveillance cultures or screening of high risk patients at the beginning of the examined period. Hand hygiene measures, personal protection equipment for infection control and regular room cleaning are mandatory in the Hospital. Antibiotic drugs monitoring is required for carbapenems, polymixins, tigecyclin, linezolid, vancomycin. Patients signed informed consent for data treatment. Bacterial identification All strains were identified in our Microbiology Centre with standard microbial methods and semiautomated Vitek-2 system provided confirmation and susceptibility testing. Results of susceptibility testing were interpreted according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints (6). In particular carbapenems susceptibility was considered with Minimum Inhibitory Concentrations (MIC) 2 mg/l and resistance with MIC 8 mg/l. Determination of enzyme type was obtained in some isolation. The modified phenotypic Hodge test was performed for isolates that exhibited reduced susceptibility to imipenem or meropenem on disk diffusion (zone of inhibition diameter 23 mm), as recommended by CLSI (7). The presence of blakpc-3 was confirmed by polymerase chain reaction (PCR) amplification using the primers KPC-F (5ʹ -ATGTCACTGTATCGCCGTCT-3ʹ ) and KPC-R (5ʹ -TTTTCAGAGCCTTACTGCCC-3ʹ ) using heat-extracted DNA as a template (8). For genotyping, random amplification of polymorphic DNA (RAPD) PCR was performed using the primer 1254 (5ʹ -CCGCAGCCAA-3ʹ ), as described previously (9). Study endpoint We collected isolations of CRKPs in order to describe characteristics of infected patients and their outcome. We evaluated epidemiologic data, patient s related morbidities and response to antibiotic therapies. The endpoint was to have a better comprehension of the phenomenon and describe retrospectively how we managed an outbreak in year Results In 2011 only 2 patients had positive cultures for CRKP; they were elderly male patients (age 81 and 88) both with multiple risk factors for hospital related infections (diabetes mellitus II, bed resting syndrome, neurological impairment); cultures were positive on pre-sacral wounds: patients were considered colonized and did not receive any systemic antibiotic therapy, with no impact on mortality. In 2012 we reviewed a total of 57 isolations among 21 patients. The mean age of the cohort was 77,6 (range 52-89), 6 males, 15 females. Cultures were positive in different specimens (percentages referred to infections/patients): urines 71,4% (15/21), blood 9.52% (2/21), upper respiratory tract 9.52 % (2/21), wounds 9,52% (2/21). One patient with a urinary tract infection (UTI) treated with success with gentamycin, died ten months later with CRKP bloodstream infection (post-mortem report). All isolations were hospital related (after at least 72 hours from the admission). Comorbidities analyzed were heart failure (HF), diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), solid tumors, hematological malignancies, renal failure and liver dysfunction; five patients had no comorbidities, five had one. The number of patients who had two or more comorbidities was eleven; most prevalent comorbidities were HF (8
3 Management of Klebsiella pneumoniae KPC outbreak in internal medicine 825 pts), hematological malignancies (8 pts, 1 multiple myeloma, 4 non-hodgkin lymphomas, 1 myelodisplastic syndrome, 1 primary myelofibrosis, 1 acute lymphoblastic leukemia), DM and renal failure (both 7 pts). Other patients presented solid tumors (4 pts), COPD (2 pts), liver dysfunction (1 pt). Most relevant infection-associated risk factors were identified in presence of devices such as urinary catheter (UC) (76% of patients) or central venous catheter (CVC) (47% of patients). Antibiotic therapy was tailored on the single patient and the choice of the drug was defined together with Infectious Disease Specialist. Six patients considered colonized or in poor general conditions were not treated (two patient with isolation from wounds, one from sputum and three from urines). Response to therapy was considered with clinical conditions and negativity of at least two consecutive cultures. Drug used were: gentamycin (response 4 out of 11), colistin plus tigecyclin (response 0 out of 1), colistin (response 0 out of 1), piperacillin/tazobactam (response 0 out of 1), fosfomycin (response 0 out of 1), amikacin (response 1 out of 1), combination therapy with colistin plus gentamyicin plus tigecyclin (response 1 out of 1). Response to therapy was 40% in treated patients. Overall crude mortality of the 2012 cohort was 47%. In vitro colistinresistance was present in 23.7% of the isolations. One patient received more than one line of therapy without success (fosfomycin, gentamycin and colistin). In 2013 we observed a decreasing number of isolations with 6 cases. Four patients carried a hematologic malignancy; infections risk factors were represented by devices: one patient had UC, one had CVC, two patients had both UC and CVC, one patient had UC, CVC and an abdominal drainage; only one patient did not have any device. Cultures were positive on urines (two patients), blood and abdominal drainage (one patient), blood (one patient), sputum (one patient) and bronchial-alveolar lavage (one patient). Two patients did not receive any treatment (one patient with poor general conditions and one patient with blood cultures resulted positive post mortem). The other patients received antimicrobial therapy: gentamycin (response 1 out of 1), gentamicin plus meropenem (response 0 out of 1), gentamycin plus high dose meropenem plus tygeciclin (response 0 out of 1), gentamycin plus high dose meropenem plus tygeciclin plus inhaled colistin (response 1 out of 1, patient affected by CRKP severe pneumonia). The response rate was 50% and overall mortality of 2013 patients was 33.3%. In conclusion, in three years of surveillance we observed 29 patients with CRKP isolation: 17 urinary tract infections (response 6/13), 4 blood stream infections (response 1/3), 4 respiratory tract infections (response 1/3), 4 skin and soft tissue infections/colonization (not treated); crude mortality was 51% and global response to therapy was 42,1% on 19 treated patients. Patient treatments can be seen in Table 1. Discussion Urinary tract infections (n17) Type of infection (n pts responders/n pts treated) Bloodstream infections (n4) Respiratory tract infections (n4) Skin and soft tissue infections/colonizations (n4) Gentamycin 5/10 0/0 0/1 0/0 Amikacin 1/1 0/0 0/0 0/0 Piperacillin/tazobactam 0/1 0/0 0/0 0/0 Fosfomycin 0/1 0/0 0/0 0/0 Colistin 0/1 0/0 0/0 0/0 Gentamycin + meropenem 0/0 0/0 0/1 0/0 Colistin +Tigecyclin 0/0 0/1 0/0 0/0 Colistin + Gentamycin + Tigecyclin Meropenem HD + Gentamycin + Tigecyclin Meropenem HD + Gentamycin + Tigecyclin + inhaled Colistin 0/0 1/1 0/0 0/0 0/0 0/1 0/0 0/0 0/0 0/0 1/1 0/0 No therapy Table 1: Antibiotic therapy related to source of infection. Treatment was decided and tailored on the single patient. A single patient could have been treated with more than one line. According to clinical data, not every patient was treated. (Note HD = high dose, 2 or 3 grams three times a day). In Europe until 2009, CRKP spread was limited to Greek and Cyprus. In 2010 Italy became heavily involved with prevalence in the invasive isolation of about 15%. From the first case described from Giani, other Italian isolations showed the presence of KPC type 2 and even worse, the appearance of horizontal transmission of
4 826 Andrea Bellodi, Lisette Del Corso et Al colistin-resistant KPC-3 positive CRKP in Palermo in Data collected from EARS net report a dramatic increase of carbapenem-resistance from 2006 to 2011 (1-2% to near 30%) (10,11). As for our ward, the situation was controlled until In 2011 only 2 patients had positive cultures for CRKP; except for the first four sporadic cases from December 2011 to May 2012, all 2012 isolations were collected after an index case, a female patient affected by tetanus, who had prolonged stay in ICU and was transferred to our unit in May She had multiple devices: UC, CVC and tracheostomy; she also had bed rest syndrome with cognitive impairment determining total dependence on health care personnel. During her hospitalization in ICU she was colonized with multiple nosocomial bacteria, such as Acinetobacter baumannii and CRKP. Cultures were positive in urine and aspiration from tracheostomy. Nursing management was quite demanding. After that, in the second half of the year, number of CRKP isolation dramatically increased taking the proportion of a real outbreak. Infection control measures were taken after two consecutive cases in June Timeline of isolations can be seen in Figure 1. Figure 1: CRKP isolations timeline. Infected patients were isolated in a single room or transferred to Infectious Disease Unit when possible; cohorts of positive patients were disposed when necessary. Physicians and all health care operators were informed about the situation and strict hygienic measures were adopted: more accurate hand hygiene with chlorine bases soap, accurate room and furniture cleaning and disinfection with chlorexidine and alcoholic agents after discharge of a positive patient, screening of other patients at risk of contamination with rectal swab. CRKP isolations in 2013 were still high in comparison of 2011, but the 2012 outbreak was contained and the major awareness of the problem produced systematic new measures for infection control: screening with rectal swab for CRKP for patients admitted from other Hospitals or wards, sudden isolation of colonized/infected patients, more accurate attention to environmental and personal hygiene (application of personal protection devices such as single use gloves and cloaks, disinfection with chlorine agents). Progressive gain in resistance of the isolated strains is another matter of concern. During autumn 2012 strains with low susceptibility to colistin became more frequent, probably due to the antibiotic selective pressure. The bacteria showed high capability to adapt to antibiotics. Tumbarello and colleagues recently demonstrated the superior efficacy of combination therapy in CRKP blood stream infections; in particular, their experience on 125 patients, showed that mortality of patients treated with monotherapy (colistin or tygeciclin) compared to patient treated with combination therapy with carbapenem was significantly higher (66,7% vs 12,5%) (12). As for our experience we can only make observation on small number of patients, but it is interesting to observe that in one particular patient, CRKP showed progressive resistance to every single antibiotic administrated to eradicate the infection (fosfomicyn, gentamicin and then colistin); therefore combination therapy seems to be the better choice, especially for most severe cases. Maybe a little space for single agent therapy could be reserved to aminoglycosides: data on 55 patients from 15 different papers demonstrates a response rate to aminoglycosides treatment of about 75%(13). Gentamycin and amikacin response rate in our cohort was 6 out of 12; more data are needed to better define the efficacy of monotherapy, which can be an option in selected patients. It is important to underline that patients treated with combination therapy in our experience had a good result even if their infections were severe (bloodstream infection and pneumonia, both patients with hematological malignancies); unfortunately we have no statistic prove to support these hypothesis, but, even according to current literature, combination therapy with colistin plus tygeciclin, high dose carbapenems and aminoglycosides, is a chance of life sparing treatment in CRKP infections, thus not yet codified in dedicated guidelines. Another matter of interest deals with patients without signs of infection that resulted positive for CRKP intestinal colonization. Should we discharge these patients home or try to eradicate the coloniza-
5 Management of Klebsiella pneumoniae KPC outbreak in internal medicine 827 tion? Is a strategy of eradication cost-effective? According to our opinion at least a chance to eradicate CRKP is mandatory in patient receiving immune-chemotherapy or surgery; mortality related to a potential infection in these patients is relevant. Oral gentamycin seems to be an option for these patients, with promising results at least in a short period of time (14). As for other patients, a local registry of CRKP carriers could be an interesting option in order to give further information to clinicians that could be involved in the management of these patients. This approach could spare costs of drugs, comorbidities, days of hospitalization and infection of other patients. Conclusion Klebsiella pneumoniae KPC is an important cause of morbidity and mortality; efficiency of single agent antibiotic therapy against CRPK seems to be not satisfying. Furthermore colistin resistance is another important matter of concern: combination therapy could be a valid option to eradicate CRKP and avoid development of other resistance. Dedicated guidelines of new combination therapy are required to have a more rapid and accurate management of these severe infections. Moreover, we suggest a carbapenem-sparing strategy when possible in order to reduce the incidence of new carbapenemase producing bacteria. Finally, a severe strategy of surveillance and containment of infected patients with strict hygiene procedures is required to avoid dissemination and hospital outbreaks. References 1) Yigit H, Queenan AM, Anderson JG, Domenech- Sanchez A, Biddle JW, et al. Novel carbapenemhydrolyzing beta lactamase KPC-1 from a resistant strain of Klebsiella Pneumoniae. Antimicrob agents chemother 2001; 45: ) Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella Pneumoniae carbapenemase producing bacteria. Lancet Infect Dis 2009 apr; 45(4): ) Arnold RS, Thom KA, Sharma S, Phillips M, Kristie Johnson J, Morgan DJ. Emergence of Klebsiella pneumoniae carbapenemase producing bacteria. South Med J 2011 Jan; 104(1): ) Giani T, D Andrea MM, Pecile P, Borgianni L, Nicoletti P, et al. Emergency in Italy of Klebsiella Pneumoniae sequence type 258 producing KPC-3 carbapenemase. J Clin Microbiol 2009; 47: ) Endimiani A, Depasquale JM, Forero S, Perez F, Hujer AM, et al. Emergency of blakpc-containg Klebsiella Pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system. J antimicrob chemother 2009; 64: ) European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical breakpoints. EUCAST. [Accessed 12 jan 2013]. Available at: 7) Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Informational Supplement. Clinical and Laboratory Standards Institute CLSI, Wayne, PA (2010). Available at: 8) Bradford PA, Bratu S, Urban C, Visalli M, Mariano N, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39 (1): ) Nowrouzian F, Hesselmar B, Saalman R, Strannegard IL, Aberg N, et al. Escherichia coli in infants intestinal microflora: colonization rate, strain turnover, and virulence gene carriage. Pediatr Res 2003; 54: ) Annual epidemiological report: Reporting on 2010 surveillance data and 2011 epidemic intelligence data, European Centre for Disease Prevention and Control. Available at: tions/publications/annual-epidemiological-report pdf 11) Munoz-Price L, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 2013; 13: ) Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; Oct; 55(7): ) Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chmother 2010 Jun; 65(6): ) Zuckerman T, Benyamini N, Sprecher H, Fineman R, Finkelstein R, et al. SCT in patients with carbapenem resistant Klebsiella pneumoniae: a single center experience with oral gentamicin for the eradication of carrier state. Bone Marrow Transplant 2011 Sep; 46(9): Corresponding author ANDREA BELLODI, MD Clinic of Internal Medicine 3 IRCCS AOU San Martino IST Largo Rosanna Benzi , Genoa (Italy)
ALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationClin Microbiol Infect Feb;21(2):e11-3. doi: /j.cmi Epub 2014 Oct 29.
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is posted here by agreement between Elsevier and the University of Turin. Changes resulting from the publishing process
More informationEmergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong. Title. Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH
Title Emergence of Klebsiella pneumoniae ST258 with KPC-2 in Hong Kong Author(s) Ho, PL; Tse, CWS; Lai, EL; Lo, WU; Chow, KH Citation International Journal Of Antimicrobial Agents, 2011, v. 37 n. 4, p.
More informationRevised AAC Version 2» New-Data Letter to the Editor ACCEPTED. Plasmid-Mediated Carbapenem-Hydrolyzing β-lactamase KPC-2 in
AAC Accepts, published online ahead of print on 3 December 2007 Antimicrob. Agents Chemother. doi:10.1128/aac.01180-07 Copyright 2007, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationCarbapenemase Producing Enterobacteriaceae: Screening
Carbapenemase Producing Enterobacteriaceae: Screening Dr David Harvey Consultant Microbiology and Infection Prevention and Control Nov 2015 Aims Is CPE a problem? Does screening have the potential to help?
More informationGuidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011
Guidance on screening and confirmation of carbapenem resistant Enterobacteriacae (CRE) December 12, 2011 Objectives: To discuss the guidelines for detection of CRE in the laboratory setting. To review
More informationKPC around the world Maria Virginia Villegas, MD, MSC
KPC around the world Maria Virginia Villegas, MD, MSC Scientific Director Bacterial Resistance and Nosocomial Infections Research Area International Center for Medical Research and Training, CIDEIM, Cali,
More informationPublic Health Surveillance for Multi Drug Resistant Organisms in Orange County
Public Health Surveillance for Multi Drug Resistant Organisms in Orange County Matt Zahn, MD Medical Director Epidemiology and Assessment Orange County Public Health Antimicrobial Mechanisms of Action
More informationRecommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals
Recommendations for the Management of Carbapenem- Resistant Enterobacteriaceae (CRE) in Acute and Long-term Acute Care Hospitals Minnesota Department of Health 11/2011 Infectious Disease Epidemiology,
More informationDifferentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test
Original article: Differentiation of Carbapenemase producing Enterobacteriaceae by Triple disc Test Manish Bansal 1, Nitya Vyas 2, Babita Sharma 3, R.K.Maheshwari 4 1PG Resident, 2 Professor, 3 Assistant
More information10/4/16. mcr-1. Emerging Resistance Updates. Objectives. National Center for Emerging and Zoonotic Infectious Diseases. Alex Kallen, MD, MPH, FACP
National Center for Emerging and Zoonotic Infectious Diseases Emerging Resistance Updates Alex Kallen, MD, MPH, FACP Lead Antimicrobial Resistance and Emerging Pathogens Team Prevention and Response Branch
More informationInfection Control Strategies to Avoid Carbapenam Resistance in Hospitals. Victor Lim International Medical University Malaysia
Infection Control Strategies to Avoid Carbapenam Resistance in Hospitals Victor Lim International Medical University Malaysia Outline of Lecture 1. Carbapenam resistance 2. Epidemiology of carbapenam resistance
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationCarbapenem-resistant Enterobacteriaceae (CRE): Coming to a hospital near you?
Carbapenem-resistant Enterobacteriaceae (CRE): Coming to a hospital near you? Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust www.reflectionsipc.com @jonotter Contents What s the problem?
More informationDetermining the Optimal Carbapenem MIC that Distinguishes Carbapenemase-Producing
AAC Accepted Manuscript Posted Online 8 August 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.00838-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 1 2 Determining the
More informationST11 KPC-2 Klebsiella pneumoniae detected in Taiwan
AAC Accepts, published online ahead of print on 30 January 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.05576-11 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5
More informationResistance to Polymyxins in France
Resistance to Polymyxins in France Paris Prof. Patrice Nordmann NDM producers in Enterobacteriaceae The polymyxins; colistin and polymyxin B Colistin - Synthesis by Bacillus polymyxa spp colistinus -
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationRegional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA)
National Center for Emerging and Zoonotic Infectious Diseases Regional Emergence of VIM producing carbapenem resistant Pseudomonas aeruginosa (VIM CRPA) Chris Prestel, MD Epidemic Intelligence Service
More informationGuidance for Control of Infections with Carbapenem-Resistant or Carbapenemase-Produc... Producing Enterobacteriaceae in Acute Care Facilities
Page 1 of 6 Weekly March 20, 2009 / 58(10);256-260 Guidance for Control of Infections with Carbapenem-Resistant or Carbapenemase- Producing Enterobacteriaceae in Acute Care Facilities Infection with carbapenem-resistant
More informationEnterobacteriaceae? ECDC EVIDENCE BRIEF. Why focus on. Update on the spread of carbapenemase-producing Enterobacteriaceae in Europe
ECDC EVIDENCE BRIEF November 2015 Update on the spread of carbapenemase-producing Enterobacteriaceae in Europe Summary of the May 2015 expert assessment The EuSCAPE project This ECDC Evidence Brief identifies
More informationAppendix B: Provincial Case Definitions for Reportable Diseases
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix B: Provincial Case Definitions for Reportable Diseases Disease: Carbapenemase-producing Enterobacteriaceae (CPE) infection or
More informationAAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi: /aac
AAC Accepts, published online ahead of print on 13 October 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00931-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationHelen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); July 2014.
Annual survey of extended-spectrum -lactamase (ESBL)-producing Enterobacteriaceae, 2013 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research
More informationConsultation on the Revision of Carbapenem Breakpoints
Consultation on the Revision of Carbapenem Breakpoints July 2018 Please send comments to the EUCAST Scientific Secretary at jturnidge@gmail.com by September 15. EUCAST revision of carbapenem breakpoints
More informationThe Carbapenemase Producing Enterobacteriaceae (CPE) Epidemic Why it matters? What it is? What Can You Do About It?
The Carbapenemase Producing Enterobacteriaceae (CPE) Epidemic Why it matters? What it is? What Can You Do About It? Martin Cormican National Lead for Health Care Associated Infection and Antimicrobial
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationRisk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study
ORIGINAL ARTICLE EPIDEMIOLOGY Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study M. Giannella 1, E. M.
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Principal Clinical Scientist in Microbiology Director of the Hospital Infection Research Laboratory Associate Director of Infection Prevention and Control
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationEmergence of non-kpc carbapenemases: NDM and more
Emergence of non-kpc carbapenemases: NDM and more --- David Livermore Health Protection Agency, UK The first acquired carbapenemase to be recognised in gram-negative bacteria was IMP-1, a metallo-type,
More informationIn-House Standardization of Carba NP Test for Carbapenemase Detection in Gram Negative Bacteria
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 7 Number 01 (2018) Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2018.701.342
More informationScreening of Carbapenem Resistant Enterobacteriaceae among Nosocomial Isolates: A Study from South India
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 460-465 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.053
More informationShaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease
Shaun Yang, PhD, D(ABMM), MLS(ASCP) CM MB CM Assistant Professor of Pathology UNM Health Sciences Center Associate Director of Infectious Disease Director of Molecular Infectious Disease TriCore Reference
More informationClinical Infectious Diseases Advance Access published July 2, 2012
Clinical Infectious Diseases Advance Access published July 2, 2012 1 Predictors of Mortality in Bloodstream Infections Caused by KPC-Producing Klebsiella pneumoniae: Importance of Combination Therapy Mario
More informationLaboratory CLSI M100-S18 update. Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator
Nebraska Public Health Laboratory 2008 CLSI M100-S18 update Paul D. Fey, Ph.D. Associate Professor/Associate Director Josh Rowland, M.T. (ASCP) State Training Coordinator Agenda Discuss 2008 M100- S18
More informationCarbapenem-resistant infections on the rise in Europe Presentation by Dr Marc Sprenger, ECDC director, Brussels Press Club, 15 November 2013
ECDC DIRECTOR S PRESENTATION Carbapenem-resistant infections on the rise in Europe Presentation by Dr Marc Sprenger, ECDC director, Brussels Press Club, 15 November 2013 For the launch of the 6th European
More informationBurns outbreaks - the UHB experience
Burns outbreaks - the UHB experience Dr Mark Garvey Mr Craig Bradley Principal Clinical Scientist in Microbiology Lead Nurse Infection Prevention Director of the Hospital Infection Research Laboratory
More information#Corresponding author: Pathology Department, Singapore General Hospital, 20 College. Road, Academia, Level 7, Diagnostics Tower, , Singapore
AAC Accepts, published online ahead of print on 21 October 2013 Antimicrob. Agents Chemother. doi:10.1128/aac.01754-13 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 Title: Escherichia
More informationEnterobacter aerogenes
Enterobacter aerogenes Piagnerelli M 1, Carlier E 1, Deplano A 3, Lejeune P 1, Govaerts D 2 1 Departments of Intensive Care and 2 Microbiology, A. Vésale Hospital. 6110 Montigny-le-Tilleul. 3 Department
More informationScreening and detection of carbapenemases
Screening and detection of carbapenemases For many isolates with carbapenemases the MICs of carbapenems are around the susceptible breakpoint making resistance difficult to detect - particularly with automated
More informationSpread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory
Spread of carbapenems resistant Enterobacteriaceae in South Africa; report from National Antimicrobial Resistance Reference Laboratory Olga Perovic*, Ashika Singh-Moodley, Samantha Iyaloo 5 th November
More informationCarbapenems and Enterobacteriaceae
Title Carbapenems and Enterobacteriaceae Presenter s details NHLS Dr Khine Swe Swe/Han FC Path ( Micro), SA MMed( micro), SA DTMH(Wits univ),sa PDIC(Stellen univ)sa MB,BS(Yangon),Myanmar Pathologist,Consultant/Lecturer,
More informationBefore an outbreak - what to do after first MDR Gram-negatives enter your hospital?
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London j.otter@imperial.ac.uk @jonotter Blog: www.reflectionsipc.com Slides:
More informationAcademic Perspective in. David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic resistance PHE
Academic Perspective in Emerging No, we can t Issues treat of carbapenemase Resistance and ESBL in Gram-ve producers Bacteria based on MIC David Livermore Prof of Medical Microbiology, UEA Lead on Antibiotic
More informationCarbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention
HEALTHCARE EPIDEMIOLOGY Robert A. Weinstein, Section Editor INVITED ARTICLE Carbapenem-Resistant Enterobacteriaceae: Epidemiology and Prevention Neil Gupta, 1,2 Brandi M. Limbago, 2 Jean B. Patel, 2 and
More informationGlobal Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE)
Global Epidemiology of Carbapenem- Resistant Enterobacteriaceae (CRE) Mitchell J. Schwaber, MD MSc Director, National Center for Infection Control Ministry of Health State of Israel November 27, 2012 1
More informationCarbapenemases in Enterobacteriaceae: Prof P. Nordmann Bicêtre hospital, South-Paris Med School
Carbapenemases in Enterobacteriaceae: 2012 Prof P. Nordmann Bicêtre hospital, South-Paris Med School March 21, 2012 Trends in Molecular Medecine NDM IMP OXA-48 KPC VIM ALERT VI M KPC KPC NDM I MP OXA-
More informationHOSPITAL INFECTION CONTROL
HOSPITAL INFECTION CONTROL Objectives To be able to define hospital acquired infections discuss the sources and routes of transmission of infections in a hospital describe methods of prevention and control
More informationDetection of the KPC-2 Carbapenem-Hydrolyzing Enzyme in Clinical Isolates of ACCEPTED
JCM Accepts, published online ahead of print on April 00 J. Clin. Microbiol. doi:./jcm.00-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationDiscussion points CLSI M100 S19 Update. #1 format of tables has changed. #2 non susceptible category
Discussion points 2009 CLSI M100 S19 Update Nebraska Public Health Laboratory Changes most important to routine antimicrobial susceptibility testing. Documents available Janet Hindler discussion slide
More informationEducational Workshops 2016
Educational Workshops 2016 Keynote CPE Screening We are grateful to Dr Andrew Dodgson, Consultant Microbiologist, Public Health England and Central Manchester Hospitals NHS Foundation Trust Terminology
More informationSensitivity of Surveillance Testing for Multidrug-Resistant Gram-Negative Bacteria in the
JCM Accepts, published online ahead of print on 20 August 2014 J. Clin. Microbiol. doi:10.1128/jcm.02369-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 Sensitivity of Surveillance
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationRAPID COMMUNICATION. Maura S. de Oliveira, I Silvia Figueiredo Costa, II Ewerton de Pedri, II Inneke van der Heijden, II Anna Sara S.
RAPID COMMUNICATION The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
More informationPhenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae
ISSN: 2319-7706 Volume 4 Number 6 (2015) pp. 547-552 http://www.ijcmas.com Original Research Article Phenotypic Detection Methods of Carbapenemase Production in Enterobacteriaceae Sathya Pandurangan 1,
More informationIn Vitro Activity of Ceftazidime-Avibactam Against Isolates. in a Phase 3 Open-label Clinical Trial for Complicated
AAC Accepted Manuscript Posted Online 21 November 2016 Antimicrob. Agents Chemother. doi:10.1128/aac.01820-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10
More informationNational Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats
National Center for Emerging and Zoonotic Infectious Diseases The Biggest Antibiotic Resistance Threats Jean B. Patel, PhD, D(ABMM) Science Lead, Antibiotic Resistance and Coordination Unit Centers for
More informationThe CLSI Approach to Setting Breakpoints
The CLSI Approach to Setting Breakpoints Jean B. Patel, PhD, D(ABMM) Deputy Director, Office of Antimicrobial Resistance Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic
More informationARTICLE IN PRESS International Journal of Antimicrobial Agents xxx (2010) xxx xxx
International Journal of Antimicrobial Agents xxx (2010) xxx xxx Contents lists available at ScienceDirect International Journal of Antimicrobial Agents journal homepage: http://www.elsevier.com/locate/ijantimicag
More information9/7/2017. If You Did This Today You Probably Got Poo On Your Hands Do You Know How to Get it Off! The Tongue Twister & The Pantomine TITLE
TITLE Martin Cormican National Lead for Health Care Associated Infection and Antimicrobial Resistance hcainational.lead@hse.ie If You Did This Today You Probably Got Poo On Your Hands Do You Know How to
More informationHOSPITAL EPIDEMOLOGY AND INFECTION CONTROL: STANDARD AND TRANSMISSION-BASED ISOLATION
Appendix 1: Carbapenem-Resistant Enterobacteriacaea (CRE) I. Definition: 2015 CDC definition of CRE are Enterobacteriaceae 1 that are: A. Resistant to any carbapenem antimicrobial (i.e., minimum inhibitory
More informationUpdate on CLSI and EUCAST
Update on CLSI and EUCAST 1 Completed work» Cephalosporin breakpoints for Enterobacteriaceae ESBL screens MIC versus resistance mechanism» Carbapenem breakpoints for Enterobacteriaceae Modified Hodge Test»
More informationEmergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011.
Emergence of carbapenemase-producing Enterobacteriaceae in France, 2004 to 2011. Sophie Vaux, Anne Carbonne, Jean-Michel Thiolet, Vincent Jarlier, Bruno Coignard, the RAISIN and Expert Laboratories Group
More informationNavigating Through Current and Emerging Issues in Outbreaks
Navigating Through Current and Emerging Issues in Outbreaks 7th GCC Conference on Infection Prevention and Control December 1-3, 2013 Kuwait City, Kuwait William R. Jarvis, M.D. Jason and Jarvis Associates,
More informationThe Year in Infection Control
The Year in Infection Control Andie Lee Departments of Infectious Diseases and Microbiology Royal Prince Alfred Hospital Sydney, Australia 1 1.223 million Pubmed publications last 12 months 2 Selection
More informationDetecting CRE. what does one need to do?
5 th ICAN Conference, Harare 4 th November 2014 Room 2: 10:30-12:00 Detecting CRE (Carbapenem-resistant Enterobacteriaceae) what does one need to do? Dr Nizam Damani Associate Medical Director Infection
More informationCarbapenem Disks on MacConkey agar as screening methods for the detection of. Carbapenem-Resistant Gram negative rods in stools.
JCM Accepts, published online ahead of print on 7 November 2012 J. Clin. Microbiol. doi:10.1128/jcm.02878-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 Carbapenem Disks
More informationEnterobacteriaceae with acquired carbapenemases, 2016
Enterobacteriaceae with acquired carbapenemases, 2016 Background The acquired or transferable (as opposed to chromosomally encoded) carbapenemases found in Enterobacteriaceae belong to three of the four
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More informationReporting blood culture results to clinicians: MIC, resistance mechanisms, both?
Reporting blood culture results to clinicians: MIC, resistance mechanisms, both? Christian G. Giske, MD, PhD Senior Consultant Physician/Associate Professor Department of Clinical Microbiology Karolinska
More informationCefotaxime Rationale for the EUCAST clinical breakpoints, version th September 2010
Cefotaxime Rationale for the EUCAST clinical breakpoints, version 1.0 26 th September 2010 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised by the European
More informationThe Public Health Benefit of CRE Colonization Testing
The Public Health Benefit of CRE Colonization Testing Allison C Brown, PhD MPH Team Lead, AR Capacities and Special Studies Division of Healthcare Quality Promotion CDC Carbapenem Resistance Serious threat
More informationMHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions
MHSAL Guidelines for the Prevention and Control of Antimicrobial Resistant Organisms (AROs) - Response to Questions Dr. Andrew Walkty Medical Microbiologist, Diagnostic Services Manitoba (DSM) June. 17,
More information2018 CNISP HAI Surveillance Case definitions
2018 CNISP HAI Surveillance Case definitions The following case definitions for the surveillance of healthcare-associated infections (HAIs) are used by all acute-care hospitals that participate in the
More informationDevelopment of a phenotypic method for fecal carriage detection of OXA-48-producing
JCM Accepts, published online ahead of print on 11 May 2011 J. Clin. Microbiol. doi:10.1128/jcm.00055-11 Copyright 2011, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationDiagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London
Diagnosis of CPE: time to throw away those agar plates? Jon Otter, PhD FRCPath Guy s and St. Thomas NHS Foundation Trust / King s College London Disclosures I am employed part-time by Bioquell I have research
More informationORIGINAL INVESTIGATION. Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City
ORIGINAL INVESTIGATION Rapid Spread of Carbapenem-Resistant Klebsiella pneumoniae in New York City A New Threat to Our Antibiotic Armamentarium Simona Bratu, MD; David Landman, MD; Robin Haag, RN; Rose
More informationSurveillance of Enterococci in Belgium. M. Ieven, K. Loens, B. Jans and H. Goossens
Surveillance of Enterococci in Belgium M. Ieven, K. Loens, B. Jans and H. Goossens Surveillance of Enterococci in Belgium Overview Introduction and epidemiological surveillance Results of isolates received
More informationDetection of Carbapenem Resistant Enterobacteriacae from Clinical Isolates
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 5 Number 5 (2016) pp. 864-869 Journal homepage: http://www.ijcmas.com Original Research Article http://dx.doi.org/10.20546/ijcmas.2016.505.089
More informationActivity of tigecycline alone and in combination with colistin and meropenem against carbapenemase
Activity of tigecycline alone and in combination with colistin and meropenem against carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay Spyros Pournaras, Georgia Vrioni, Evangelia
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationPreventing & Controlling the Spread of Infection
Preventing & Controlling the Spread of Infection Contributors: Alice Pong M.D., Hospital Epidemiologist Chris Abe, R.N., Senior Director Ancillary and Support Services Objectives Review the magnitude of
More informationTreatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis
J Antimicrob Chemother 2016; 71: 2563 2568 doi:10.1093/jac/dkw178 Advance Access publication 30 May 2016 Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis Justin
More informationDetection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by MALDI- TOF mass spectrometry
JCM Accepts, published online ahead of print on 2 May 2012 J. Clin. Microbiol. doi:10.1128/jcm.01002-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6 7 8 9 10 11 12
More informationInfection Prevention & Control Core Skills Level 2
Infection Prevention & Control Core Skills Level 2 Learning outcomes Risk assessment of patients Critical examination of the situation MRSA, CDT & CPE Ongoing challenges future-proofing infection control
More informationPROFESSOR PETER M. HAWKEY
Multi-drug resistant Escherichia coli PROFESSOR PETER M. HAWKEY School of Immunity and Infection College of Medical and Dental Sciences University of Birmingham Birmingham B15 2TT Health Protection Agency
More informationEnhanced EARS-Net Surveillance REPORT FOR 2012 DATA
Enhanced EARS-Net Surveillance REPORT FOR DATA 1 In this report Main results for Proposed changes to the enhanced programme Abbreviations Used Here BSI Bloodstream Infections CVC Central Venous Catheter
More informationAdenium Biotech. Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes
Adenium Biotech Management: - Peter Nordkild, MD, CEO, ex Novo Nordisk, Ferring, Egalet - Søren Neve, PhD, project director, ex Lundbeck, Novozymes Board of Directors: - Stephan Christgau, PhD, chairman,
More informationEnhanced EARS-Net Surveillance 2017 First Half
1 Enhanced EARS-Net Surveillance 2017 First Half In this report Main results for 2017, first half Breakdown of factors by organism and resistance subtype Device-association Data quality assessment Key
More informationBlood cultures in ED. Dr Sebastian Chang MBBS FACEM
Blood cultures in ED Dr Sebastian Chang MBBS FACEM Why do we care about blood cultures? blood cultures are the most direct method for detecting bacteraemia in patients a positive blood culture: 1. can
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationSSRG International Journal of Medical Science (SSRG-IJMS) volume 2 Issue 4 April 2015
Utilization of MacConkeyMeropenem screening Agar for the Detection of Carbapenem Resistanant Enterobacteriaceae in a tertiary care hospital Sanjeev Kumar 1, Anamika Vyas 2, S.K.Mehra 3 1,3 Department of
More informationNightmare Bacteria. Disclosures. Technician Objectives. Pharmacist Objectives. Carbapenem Resistance in Carbapenem Resistance in 2017
Nightmare Bacteria How to Deal with the Reality of Carbapenem-resistant Organisms Disclosures I have no conflicts of interest relative to the content of this presentation Matthew L. Brown, Pharm.D., BCPS
More informationCurrent concepts in combination antibiotic therapy for critically ill patients
Short Communication Current concepts in combination antibiotic therapy for critically ill patients Armin Ahmed, Afzal Azim, Mohan Gurjar, Arvind Kumar Baronia Abstract Widespread emergence of multidrug
More information